Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Monoclonal Antibodies for Multiple Sclerosis Treatment.
Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Valuing the Endangered Species Antirrhinum lopesianum: Neuroprotective Activities and Strategies for in vitro Plant Propagation.
X-linked Charcot-Marie-Tooth disease type 6 (CMTX6) patients with a p.R158H mutation in the pyruvate dehydrogenase kinase isoenzyme 3 gene.
Change in perceived health insurance coverage among people with multiple sclerosis.
[Chronic inflammatory demyelinating polyradiculoneuropathy revealing essential thrombocythemia].
Autonomic dysfunction in multiple sclerosis.
Neurological perspectives on voltage-gated sodium channels.
The TIM-3 pathway ameliorates Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Biomarker time out.
The Prognostic Utility of MRI in Clinically Isolated Syndrome: A Literature Review.
IL-17F but not IL-17A gene polymorphism confers risk to multiple sclerosis in a Chinese Han population.
Neurologic indications for therapeutic plasma exchange: 2013 update.
Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Menopause in multiple sclerosis: therapeutic considerations.
Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: An MEG source-space study.
A case of IgM paraproteinemic neuropathy associated with anti-sulfated glucuronic paragloboside (SGPG) IgG antibody without anti-myelin-associated glycoprotein (MAG) activity.
Risperidone-Induced Pisa Syndrome in MS: Resolution with Lurasidone and Recurrence with Chlorpromazine.
Increased HLA-E expression in white matter lesions in multiple sclerosis.
Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
Timing of cigarette smoking as a risk factor for multiple sclerosis.
Multiple sclerosis and mitochondrial gene variations: A review.
Natalizumab and the development of extensive brain lesions in neuromyelitis optica.
Spiritual wellbeing and perceived uncertainty in patients with multiple sclerosis in south-east Iran.
Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Pages